Diabetes mellitus and prothrombotic activity

Česká verzia

Authors: J. Malý
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Jaroslav Malý, CSc.
Published in the journal: Vnitř Lék 2010; 56(4): 284-288
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Summary

Diabetes mellitus (DM) is defined by significant hyperglycaemia representing a high risk of thrombosis in coronary as well as central and peripheral arteries. The risk of myocardial infarction in patients with type 2 diabetes is 3– 5 times higher than in non‑diabetics. This is consequent to changes in haemostasis in obese patients with type 2 diabetes, including changes to fibrinolysis, decreased fibrinolytic activity and increased thrombogenic risk, as part of the pluri‑ metabolic insulin resistance syndrome [1,2]. The REACH study evaluated more than 67 thousands of patients with a risk of arterial thrombosis or with arterial thrombosis. The patients with diabetes were separated and the results subjected to multivariate analysis; differences were confirmed between intensity of treatment in patients with ischemic heart disease and diabetes and with diabetes only. Antithrombotic therapy in diabetic patients with no clinical signs of arterial thrombosis was less intensive [3].

Key words:
diabetes mellitus – arterial thrombosis – insulin resistance thrombosis – prothrombotic activity

Zdroje

1. Juhan‑ Vague I, Alessi MC. PAI‑ l, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656– 661.

2. Juhan‑ Vague I, Morange P, Renucci JF et al. Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999; 10 (Suppl 1): S25– S28.

3. Parhofer KG, Zeymer U, Stark RG et al. In germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis – results from the REACH registry. Exp Clin Endocrinol Diabetes 2010;118: 51– 56.

4. Škrha J, Hodinář A, Kvasnička J et al. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med 1996; 13: 800– 805.

5. Kvasnička J, Škrha J, Perušičová J et al. The occurrence of the cardiovascular risk factors – fibrinogen, t‑ PA, PAI‑ l, and inflammation in insulin‑dependent diabetes mellitus (IDDM) and in non‑insulin‑dependent diabetes mellitus (NIDDM). Cor Vasa 1997; 39: 146– 150.

6. Galajda P, Martinka E, Kubisz P et al. Hemostáza u chorých s diabetes mellitus. Markery dysfunkce endotelu. Vnitř Lék 1996; 42: 676– 679.

7. Amiral J. Markers of prethrombotic/ hypercoagulable states of blood and vascular cell origins. In: Hemostasis and Thrombosis: Multicellular processes. Paris: Stago 1996.

8. De Lorenzo F, Mukherjee M, Karziola Z et al. Association of overall adiposity rather than body mass index with lipids and procoagulant factors. Thromb Haemost 1998; 80: 603– 606.

9. De Pergola G, De Mitrio V, Giorgino F et al. Increase in both pro‑thrombotic and anti‑thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997; 21: 527– 535.

10. De Pergola G, De Mitrio V, Sciaraffia Met al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors Irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997; 46: 1287– 1293.

11. Fendri S, Roussel B, Lormeau B et al. Insulin sensitivity, insulin action, and fibrinolysis activity in non diabetic and diabetic obese subjects. Metabolism 1998; 47: 1372– 1375.

12. Galajda P, Kubisz P, Mokáň M. Multikompartmentový a multifaktoriálny model produkcie inhibítora plazminogénového aktivátora (PAI‑1). Vnitř Lék 1998; 44: 718– 721.

13. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22 (Suppl 3): C25– C30.

14. Osende J, Badimon J, Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307– 1312.

15. Trovati M, Anfossi G. Influence of insulin and insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35– 40.

16. Mokán M, Galajda P, Prídavková D et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Res Clin Pract 2008; 81: 238– 242.

17. Samad F, Loskutoff DJ. Hemostatis gene expression and vasculat disease in obesity: insights from studies of genetically obese mice. Thromb Haemostas 1999; 82: 742– 747.

18. Kvasnička J, Škrha J, Perušičová J et al. Koncentrace tkáňového aktivátoru plazminogenu (T‑ PA), jeho inhibitoru (PAI‑ l) a fibrinogenu v krevní plazmě pacientů s diabetes mellitus 1. a 2. typu. Čas Lék Čes 1996; 135: 174– 177.

19. Dunn E, Ariëns R, Grant P. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198– 1209.

20. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44– 6S52.

21. Gentile NT, Vaidyula VR, Kanamalla U et al. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost 2007; 98: 1007– 1013.

22. Ranieri R et al. Mean platelet volume in obesity its relation to visceral fat and to cardiovascular risk factor. Int J Obesity 1996; 20 (Suppl 4): 115S.

23. Chu S, Becker RC, Berger PB et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‑analysis. J Thromb Haemost 2010; 8: 148– 156.

24. Vinik A, Erbas T, Park T et al. Platelet dysfunction in type II diabetes. Diabetes Care 2001; 24: 1476– 1485.

25. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157– 172.

26. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high‑risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106– 2110.

27. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009; 23: 375– 388.

28. Malý J, Pecka M, Pleskot M et al. Změny aktivity destiček při invazivních kardiologických výkonech. Vnitř Lék 1996; 42: 314– 319.

29. Baldi S, Natali A, Buzzigoli G et al. In vitro effect of insulin on intracellular calcium concentrations: relation to insulin resistance. Metabolism 1996; 45: 1402– 1407.

30. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008; 6: 313– 328.

31. Anfossi G, Mularoni E, Burzacca S et al. Platelet resistance to nitrates in obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 121– 126.

32. Betteridge D, El Tahir K, Reckless J et al. Platelets from diabetic subjects show diminished sensitivity to prostacycline. Eur J Clin Invest 1982; 12: 395– 398.

33. Westerbacka J, Yki‑ Järvinen H, Turpeinen A et al. Inhibition of platelet‑ collagen interaction. An in vivo action of insulin is abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167– 172.

34. Enomoto M, Adachi H, Yamagishi SI et al. Positive association of serum advanced glycation end products with thrombogenic markers in humans. Metabolism 2006; 55: 912– 917.